AbbVieABBV

Business Snapshot

• AbbVie Inc. is a U.S.-listed common stock trading on the NYSE in USD. The supplied SEC linkage identifies AbbVie Inc. (CIK 1551152).
• The payload does not provide business-segment, product, or guidance details, so this briefing focuses on the reported financials, insider data, and price indicators provided.

Financial Trends

• Revenue: Revenue rose from $15.776B in 2025-09-30 to $16.618B in 2025-12-31 (+$0.842B, +5.3%), then fell to $15.002B in 2026-03-31 (-$1.616B, -9.7%) before rebounding to $16.990B in 2026-06-30 (+$1.988B, +13.3%). Latest revenue is $1.214B (+7.7%) above the earliest period shown.
• Operating margin: Reported margins were 12.07% → 90.71% → 26.60% → 37.86% across the four periods. The latest improved 11.26 percentage points from March, but remains 25.79 points above September’s level. The exceptionally high December figure and sharp swings warrant caution when interpreting the series; the payload does not explain the drivers.
• Net margin: 1.18% → 10.93% → 4.63% → 21.27%. It rose 16.64 points from March to June and 20.09 points versus September. The reported net-income sequence likewise moved from $186M to $1.816B, down to $695M, then up to $3.613B.
• Gross margin: Only the 2025-12-31 figure is supplied (72.61%); a four-period trend cannot be established.
• Free cash flow: FCF was $12.927B → $17.816B → $3.564B → $6.678B. It fell $14.252B (-80.0%) from December to March, then recovered $3.114B (+87.4%) in June. Latest FCF remains $6.249B (-48.3%) below September’s reported figure.
• Balance sheet: Total assets were broadly stable, moving from $133.898B in September to $135.115B in June (+$1.217B), after reaching $136.463B in March. Shareholders’ equity stayed negative and worsened from -$2.642B in September to -$5.935B in June, with an interim improvement to -$3.270B in December. Cash moved from $5.629B to $6.569B over the period, but was volatile: $5.229B in December, $9.391B in March, then $2.822B lower in June.
• Liquidity trend: The current ratio improved from 0.72 in September to 0.81 in June, after dipping to 0.67 in December. Working capital remained negative, improving from -$10.852B to -$7.973B over the four periods, though it had deteriorated to -$14.227B in December.

Financial Health

• The latest quarter combines higher revenue, operating income, net income, and FCF than March, indicating a strong sequential rebound in the supplied figures. FCF also recovered from March’s low, but remains below both September and December.
• Liquidity ratios improved to their best listed level (current ratio 0.81) and negative working capital narrowed to -$7.973B. Still, current liabilities exceed current assets in every listed period.
• Negative shareholders’ equity (-$5.935B) limits the usefulness of the supplied debt/equity ratio, which is negative in all four periods. The payload does not provide a separate debt balance, so debt levels or leverage changes cannot be assessed directly.
• Large quarter-to-quarter swings in reported margins and cash flow make a single-period reading less reliable. No guidance, valuation multiples, or explanations for these swings are supplied.

Insider Activity

• Insider sentiment for 2026-07-01 through 2026-09-29 is Neutral (-5), with $2.634M of buys across 3 transactions and $8.178M of sells across 2 transactions. Net activity is -$5.543M.
• No Forms 4/5 filings were found for 2026-08-30 through 2026-09-29. The supplied data therefore points to net selling over the broader sentiment window, but no transactions in the narrower recent window.

Multi-Timeframe Technical Context

• Only daily market data is supplied; minute- and intraday-level signals cannot be assessed. The quoted market status is pre-market.
• The 200-bar daily series shows a move from $225.00 to $266.28 (+18.35%). The current price is above the supplied EMA-12 ($263.35), EMA-26 ($260.66), EMA-50 ($255.91), SMA-20 ($260.62), SMA-50 ($257.28), and SMA-200 ($230.78)—a constructive price/average configuration.
• Momentum is positive by the supplied MACD readings (2.6937, above 2.3753 signal). Daily RSI-14 is 92.68, signaling an exceptionally stretched reading; RSI-21 is 59.6, a less extreme but still positive reading.
• Price is near the Bollinger upper band ($270.57), with the middle at $260.62 and lower band at $250.67. Current volume (4.43M) is modestly above the 20-period average (4.14M).
• The supplied session range is unusually wide ($190.75–$269.39); without more context, that low should not be treated as a confirmed support level. ATR is $4.92, indicating notable daily price movement.

Bull / Bear Cases

• Short-term bull case: Price is above all supplied daily moving averages, MACD is above its signal, and volume is slightly above its 20-period average. A sustained move through the recent/session high near $269.39 and upper Bollinger band near $270.57 would strengthen the momentum case.
• Short-term bear case: RSI-14 at 92.68 and proximity to the upper Bollinger band indicate an extended move with potential for a pullback or consolidation. A loss of the $260–$263 area would put the short-term average cluster under pressure.
• Long-term bull case: June revenue and earnings rebounded from March, while FCF recovered sharply and the current ratio and working-capital deficit improved versus the earlier periods. Price also remains above the 200-day average supplied.
• Long-term bear case: FCF is still well below the September and December readings, equity remains negative and worsened versus September, and current liabilities exceed current assets in every reported period. Margin volatility and net insider selling add uncertainty; the payload provides no guidance or business-driver detail to resolve it.

Key Levels & Triggers

• Near-term resistance: $269.39 session high, followed by the $270.57 upper Bollinger band. A sustained break above this zone would be a momentum confirmation; rejection could favor consolidation.
• Near-term support: $263.35 EMA-12, then the $260.62–$260.66 SMA-20 / EMA-26 cluster. Below that, watch $257.28 SMA-50 and $250.67 lower Bollinger band.
• Longer-term reference: $230.78 SMA-200. It is well below the current price, but the supplied data does not establish it as an immediate support target.
• Fundamental triggers to monitor: whether revenue and FCF continue to recover after their March declines; whether negative working capital and equity improve; and whether the large reported margin swings persist. No forward guidance or catalysts are provided in the payload.